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Abstract
The endolymphatic sac (ES) is an inner ear organ that is connected to the cochleo-vestibular system through the
endolymphatic duct. The luminal fluid of the ES contains a much higher concentration of proteins than any other
compartment of the inner ear. This high protein concentration likely contributes to inner ear fluid volume regulation by
creating an osmotic gradient between the ES lumen and the interstitial fluid. We characterized the protein profile of the ES
luminal fluid of patients (n = 11) with enlarged vestibular aqueducts (EVA) by proteomics. In addition, we investigated
differences in the protein profiles between patients with recent hearing deterioration and patients without hearing
deterioration. The mean total protein concentration of the luminal fluid was 554.7694.6 mg/dl. A total of 58 out of 517
spots detected by 2-DE were analyzed by MALDI-TOF MS. The protein profile of the luminal fluid was different from the
profile of plasma. Proteins identified from 29 of the spots were also present in the MARC-filtered human plasma; however,
the proteins identified from the other 25 spots were not detected in the MARC-filtered human plasma. The most abundant
protein in the luminal fluid was albumin-like proteins, but most of them were not detected in MARC-filtered human plasma.
The concentration of albumin-like proteins was higher in samples from patients without recent hearing deterioration than
in patients with recent hearing deterioration. Consequently, the protein of ES luminal fluid is likely to be originated from
both the plasma and the inner ear and considering that inner ear fluid volumes increase abnormally in patients with EVA
following recent hearing deterioration, it is tempting to speculate that albumin-like proteins may be involved in the
regulation of inner ear fluid volume through creation of an osmotic gradient during pathological conditions such as
endolymphatic hydrops.
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Introduction
The luminal part of the inner ear is filled with a low [Na+] and
high [K+] fluid that is called endolymph [1]. The unique ion
composition of this fluid is essential for maintaining hearing and
balance by providing K+ for mechanotransduction. The endo-
lymphatic sac (ES) is the only non-sensory inner ear organ. The ES
is a small structure (,15 mm2) [2] that is an extension of the
luminal compartment of the inner ear. It is situated on the
posterior fossa dura and is connected to the cochleo-vestibular
system through the endolymphatic duct (Fig. 1). The presumed
role of the ES is the regulation of the volume of endolymph [3]. If
endolymphatic volume regulation is disturbed, serious derange-
ment of inner ear function (i.e., hearing loss and dizziness) may
occur. Representative diseases arising from disturbances of
endolymphatic volume regulation are Meniere’s disease and
enlarged vestibular aqueduct (EVA) syndrome. Meniere’s disease
is a syndrome characterized by symptoms of recurrent vertigo
spells, sensorineural hearing loss, tinnitus and aural fullness. EVA
syndrome is a congenital disorder that presents profound
sensorineural hearing loss. The most common etiology of EVA
syndrome in South Asia is the mutation of the SLC26A4 gene [4],
which is also known as pendred gene. The primary pathology
involved in Meniere’s disease is endolymphatic hydrops, which is a
phenomenon wherein the volume of endolymph increases
abnormally and the endolymphatic space is distended [5]. In
addition, most cases of EVA syndrome present with a distended
ES, which may reflect increased endolymph volume [6,7,8]. So
far, the pathophysiological mechanism underlying the increases in
endolymphatic volume that occur in these disease states is unclear.
One of the prominent compositional differences between
cochleo-vestibular endolymph and the luminal fluid of the ES is
protein concentration (Fig. 1). Animal experiments have revealed
that the protein concentration of luminal fluid in the ES is
extremely high (,1600 mg/dl), about 40-fold higher than that of
cochleo-vestibular endolymph (,38–60 mg/dl) [9]. The high
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protein concentration of the luminal fluid of the ES is likely
associated with the function of the ES. In addition, the luminal
area of the ES is filled with a homogeneous substance that has
been characterized as containing heavily glycosylated proteins
(proteoglycan) [10,11]. These proteins have been reported to
generate an osmotic gradient that can trigger transport of water
into or out of the ES lumen, which consequently alters endolymph
volume. However, no reports have identified the components of
this homogeneous substance in the luminal fluid of the human ES
and no studies have verified whether this homogeneous substance
contributes to endolymphatic volume regulation under patholog-
ical conditions such as EVA syndrome or Meniere’s disease.
Currently, little is known about the protein composition of luminal
fluid in the human ES, largely because the small volumes of
sample available make the analysis of this fluid very difficult.
Moreover, the small volume of luminal fluid that can be sampled
from the human ES can be easily contaminated by surrounding
tissue fluids and blood.
This study examined the luminal fluid from patients with EVA,
enabling us to sample a large volume of luminal fluid. We also
obtained ES luminal fluid as a control from patients undergoing
acoustic tumor by aspirating the fluid after dilution with
physiologic saline. The protein profiles of these samples were
comprehensively analyzed by proteomics. We compared the
protein composition of luminal fluid between patients without
sudden hearing deterioration and patients with sudden hearing
deterioration where a sudden increase in endolymph volume was
suspected. Characterizing the protein composition of luminal fluid
and examining the changes in this composition following sudden
hearing deterioration will help elucidate the role of the ES in inner
ear fluid regulation.
Results
Protein concentration of the luminal fluid of the ES from
EVA patients
The protein concentration of the luminal fluid varied between
the samples (80,920 mg/dl) and the mean total protein
concentration was 554.7694.6 mg/dl (Table 1). We first analyzed
the association between the protein concentration and age of
patients, which was revealed to have no significance (P.0.05). The
mean protein concentration in patients with the SLC26A4
mutation was 563.1694.4 mg/dl and the mean protein concen-
tration in patients without the SLC26A4 mutation was
540.06194.9 mg/dl (Fig. 2A). These data indicate that the
protein concentration did not associate with the presence of the
SLC26A4 mutation (P.0.05). The protein concentration mea-
sured for patient 7 (no mutation in SLC26A4 or GJB2) was
extremely low relative to the other patients. In contrast, the
protein concentration of the other three patients who did not
possess the SLC26A4 mutation was not significantly reduced
compared to the other patients (P.0.05, Fig. 2A, Table 1).
However, the protein concentrations detected in patients with a
definitive histories of sudden hearing deterioration within the prior
6 months (recent hearing deterioration) tended to be significantly
lower than the protein concentrations detected in patients without
a recent hearing deterioration (P = 0.04, Fig. 2B). Specifically, the
mean protein concentration in patients without recent hearing
loss compared to those with recent hearing deterioration were
666.0690.1 mg/dl and 360.06145.1 mg/dl, respectively.
Difference in protein composition between the luminal
fluid of the ES and the plasma in EVA patients
The two dimensional gel electrophoresis (2-DE) of the plasma
protein composition for patient 1 (Fig. 3A) was similar to the
findings in normal human plasma [12]. The six most abundant
proteins in the plasma were albumin, IgG (heavy and light chain),
IgA, transferrin, antitrypsin, and haptoglobin. However, the
protein profile of the luminal fluid from the ES was different
from the protein profile of plasma. Albumin, transferrin, IgG
heavy chain, IgG light chain, and antitrypsin were also found in
the luminal fluid but IgA and haptoglobin were not identified by 2-
DE analysis of the luminal fluid (Fig. 3).
To further analyze these results, chromatographic separation of
the most abundant proteins was performed using multiple affinity
removal columns (MARC). The six most abundant plasma
proteins in the plasma nearly disappeared after MARC and
the 2-DE imaging after MARC was identical to that of normal
human plasma (Fig. 4A) [13]. However, the protein composition
(according to 2-DE imaging following MARC) was clearly
different between plasma and luminal fluid (Fig. 4A and 4B).
The most abundant protein spot (spot 1 in Fig. 4B) in the luminal
fluid corresponded to that of albumin in plasma, but this spot
remained on the gel even after MARC, unlike that of plasma. In
addition, there were multiple protein spots that were only seen in
the luminal fluid, but not in plasma.
Identification of proteins in the luminal fluid of ES from
EVA patients
MALDI-TOF MS was performed to identify the proteins
represented by each spot in the 2-DE of patient 1. The total
number of spots in the 2-DE image from the luminal fluid after
MARC was 517. A total of 58 major spots were analyzed via
MALDI-TOF MS (Fig. 5). The MALDI-TOF MS analysis
identified 55 spots as displaying significant protein scores
Figure 1. Schematic drawing of the inner ear. The inner ear
consists of the cochlea, vestibule and the endolymphatic sac. The
cochlea and vestibule, which is composed of the utricle, saccule and
three semicircular canals, extend to the endolymphatic sac through the
endolymphatic duct. One of the striking compositional differences
between cochleo-vestibular endolymph and the luminal fluid of the ES
is protein concentration (number in the parenthesis).
doi:10.1371/journal.pone.0021656.g001
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(p,0.05) and three spots were revealed not to be significant
(p.0.05). Twenty-nine of the proteins identified by MALDI-TOF
MS were detected in the MARC-filtered human plasma; however,
proteins identified from the other twenty-six spots by MALDI-
TOF MS were not represented in the MARC-filtered human
plasma [13]. Proteins found only in the luminal fluid included
hypothetical protein (gi|51476390), hypothetical protein
LOC55471 isoform 3 (gi|145701028), unnamed protein product
(gi|221043908), minichromosome maintenance complex compo-
nent 8 isoform 1 (gi|19923727), axonemal beta heavy chain
dynein type 11 (gi|15395290), KIAA1505 protein isoform CRA_a
(gi|119597447) and Rho GTPase activating protein 23
(gi|224458284), among others. These results are summarized in
Figure 5 and Tables 2 and 3. These results suggest that a portion
of the proteins in the luminal fluid is originated from the plasma;
however, many proteins in the luminal fluid are just as likely to be
originated from the ES or from other inner ear compartments.
We performed LC-MS/MS with part of the most abundant spot
(spot 1 in Fig. 5) in the 2-DE image, which was identified as a
hypothetical protein (gi|51416390) by MALDI-TOF MS, and also
the trypsinized protein of patient 1 to confirm the result. Finally,
the protein commonly detected in both samples (part of spot 1 and
trypsinized protein of patients 1) was revealed to be an unnamed
product (gi|28590), which was also similar to human albumin
(gi|4502027) but has a total of 6 different amino acids out of 609
amino acids (Fig. 6, Table 4, and Fig. S1); sequence coverage on
LC-MS/MS was 66%, score was 1659 and four unique peptide
sequence for the unnamed protein product (gi|28590) was
detected (ion scores .42 and p,0.05). However, several
albumin-like proteins were also detected in LC-MS/MS in each
Figure 2. Difference in total protein concentration of the luminal fluid in endolymphatic sac. A: The difference in total protein
concentration between patients with the SLC 26A4 mutation versus patients without the SLC26A4 mutation. Mean protein concentrations in patients
with the SLC26A4 mutation and in patients without the SLC26A4 mutation were 563.1694.4 mg/dl and 540.06194.9 mg/dl, respectively. Total
protein concentration was not significantly different (P = 0.45). B: Difference in total protein concentration between patients without recent (,6
months) hearing deterioration [HL (-)] compared to patients with recent hearing deterioration [HL (+)]. Mean protein concentrations in patients
without recent hearing loss and with recent hearing loss were 666.0690.1 mg/dl and 360.06145.1 mg/dl, respectively. The protein concentration in
patients with recent hearing loss was significantly lower than the protein concentration in patients without recent hearing loss (P = 0.04).
doi:10.1371/journal.pone.0021656.g002
Table 1. Demographics and mutation type of patients enrolled in this study.







1 34 M SLC26A4 (F572 L/H723R) - 960 61.7
2 20 M SLC26A4 (H723R/H723R) - 900 38.2
3 18 F SLC26A4 (L676Q/IVS7-2A.G) + 444 4.2
4 3 F GJB2 (V27I/E114G) - 660 14.2
5 12 F SLC26A4
(IVS7-2A.G/IVS7-2A.G)
- 620 30.5
6 10 F SLC26A4 (H723R/IVS7-2A.G) - 342 61.1
7 16 F No mutation detected + 152 0
8 2 M SLC26A4 (H723R/H723R) + 612 4.4
9 43 F No mutation detected - 920 31.8
10 21 F SLC26A4 (H723R/H723R) + 760 49.4
11 8 F No mutation detected - 800 40.2
doi:10.1371/journal.pone.0021656.t001
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sample such as chain A, crystal structure of human serum albumin
(gi|3212456; Mr, 66472; pI value, 5.67; score, 1657; sequence
coverage 70%), unnamed protein product (gi|194391080; Mr,
70362; pI value, 5.77; score, 763; sequence coverage 32%),
unnamed protein product (gi|194391112; Mr, 59573; pI value,
6.88; score, 652; sequence coverage 23%), PRO2675 (gi|7770217;
Mr, 32574; pI value, 6.14; score, 504; sequence coverage 33%)
and albumin, isoform CRA_t (gi|119626083; Mr, 58652; pI value,
6.66; score, 356; sequence coverage 27%) (Table S1). Thus, it is
more likely that spot 1 is a mixture of albumin-like proteins than
just consisting of one protein.
Recent hearing deterioration in EVA patients correlates
with decreased levels of albumin-like proteins
This study analyzed the difference in the proportion of the
largest spot (albumin-like proteins, e.g., spot 1 in Fig. 5) in the 2-
DE images of each patient. The proportion of total protein tended
to be more represented by albumin-like proteins as the protein
concentration of the luminal fluid increased (p = 0.048, R2 = 0.30,
Fig. 7). In comparing the protein compositions of the luminal fluid
between patients who suffered recent (,6 months) hearing
deterioration versus patients who did not, the most striking
difference observed was that patients with a history of recent
hearing deterioration showed a decreased proportion of the
albumin-like proteins in the 2-DE image (Fig. 8). The proportion
of albumin-like proteins in patients without recent hearing
deterioration was 39.766.4%, whereas the proportion of albu-
min-like proteins in patients with recent hearing deterioration was
14.5611.7% (Fig. 9A). The proportion of albumin-like proteins
was significantly decreased in patients who presented with recent
hearing deterioration (p = 0.034, Fig. 9A). The proportion of the
albumin-like proteins did not differ significantly with respect to the
presence of the SLC26A4 mutation. Most patients were
determined to have the SLC26A4 mutation, although one patient
Figure 3. Representative 2-DE of human plasma and luminal fluid from the endolymphatic sac without MARC (patient 1). A: 2-DE of
human plasma without MARC. B: 2-DE of luminal fluid from the human endolymphatic sac without MARC. Alb, albumin; IgG (H), IgG heavy chain; IgG
(L), IgG light chain; A-tryp, antitrypsin.
doi:10.1371/journal.pone.0021656.g003
Figure 4. Representative 2-DE of human plasma and luminal fluid from the endolymphatic sac after MARC (patient 1). A: 2-DE of
human plasma after MARC. B: 2-DE of luminal fluid from the human endolymphatic sac after MARC.
doi:10.1371/journal.pone.0021656.g004
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Figure 5. A total of 58 primary spots from the 2-DE analyzed by MALDI/TOF (patient 1). A total of 58 green-bordered spots were analyzed
via MALDI/TOF and MS. Among these 58 spots, 17 of the most abundant protein spots were numbered (1,17) and are described in Tables 3 and 4.
doi:10.1371/journal.pone.0021656.g005
Table 2. Ten most abundant protein spots identified in the luminal fluid of the endolymphatic sac from patient 2 by MALDI-TOF
MS.
Spot No. gi number Protein Name Volume (%)
1 gi|51476390 Hypothetical protein* 61.639
2 gi|51476390 Hypothetical protein 5.272
gi|11493459 PRO 2619
8 gi|7770217 PRO2675 2.383
6 gi|46981961 growth-inhibiting protein 25 1.858
gi|28332 unnamed protein product
gi|6980544 chain A, alpha1-antichymotrypsin serpin in the delta conformation (partial loop insertion)
9 gi|228311905 chain A, crystal structure of human serum albumin 0.974
10 gi|145701028 hypothetical protein LOC55471 isoform 3 0.844
11 gi|27065112 chain A, crystal structure of the transthyretin 0.737
12 gi|18655424 chain A, crystallographic analysis of the human vitamin D binding protein 0.618
13 gi|221043908 unnamed protein product 0.484
7 gi|177933 alpha-1-antichymotrypsin precursor 0.332
*, hypothetical protein (gi|51476390) was finally revealed to be a mixture of albumin-like proteins by LC-MS/MS (See table 4, figure 6, and figure S1).
doi:10.1371/journal.pone.0021656.t002
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presented the GJB2 mutation (patient 4) and several other patients
(patient 7, 8, and 11) did not possess either of the two mutations.
The proportion of albumin-like proteins did not differ between the
patients with the SLC26A4 mutation and the patients without the
mutation (P.0.05, Fig. 9B). The proportion of albumin-like
proteins was very low in patient 4 (GJB2 mutation) and patient 7
(no mutation) (Table 1); however, the number of patients with this
mutation was too small to reveal any relationship between the
mutation and the proportion of albumin-like proteins.
Albumin-like proteins in the luminal fluid from the ES of
acoustic schwannoma as a control for no hydrops
This study sought to determine whether the albumin-like
proteins were also expressed under normal conditions by
identifying proteins in the luminal fluid from the ES of acoustic
schwannoma as a control for no hydrops. The highest signal band
detected by 1-DE gel analysis of samples from these patients
corresponded to the molecular weight of the albumin-like proteins
in the 2-DE gel image of the luminal fluid from EVA patients
(Fig. 10). The band was excised and LC-MS/MS was performed.
Four types of proteins were identified by this analysis: albumin or
albumin-like protein (Table 5), immunoglobulins, ribosomal
proteins, and interferon regulatory factor 7. Albumin-like proteins
were also present in the luminal fluid of controls, and two of them,
an unnamed protein product (gi|28590) and a chain A, crystal
structure of human serum albumin, were identified by the LC-
MS/MS analysis with ES luminal fluid of EVA patients (Table 5
and Table S2). The albumin-like proteins are likely to normally
exist in the luminal fluid of ES and its concentration is likely to
change in some pathologic conditions such as sudden hearing
deterioration in EVA patients.
Discussion
The role of the ES is unclear but it has been suggested to be
involved in inner ear homeostasis and endolymphatic volume
regulation. Under normal conditions, endolymph flow from the
cochleovestibular system to the ES is thought to be minimal.
However, under pathological conditions (e.g., during endolym-
phatic hydrops), endolymph flows from the cochleovestibular
system to the ES [3]. In addition, the ES regulates endolymph
volume by absorbing fluid from the interstitial space [14]. This
volume flow is thought to serve as an important regulatory
mechanism contributing to the control of normal fluid volume.
One of the suggested mechanisms involved in endolymphatic
volume regulation is the transport of water into or out of the ES
lumen, which depends on the magnitude of the osmotic gradient
between the lumen and the interstitial space. Rask-Anderson et al.,
proposed that the intraluminal homogeneous substance in the ES
creates an osmotic gradient that contributes to endolymphatic
volume regulation, based on animal experiments [14]. The
amount of this homogeneous substance decreased in response to
increased inner ear volume load, which decreased the osmotic
gradient between the endolymph and the interstitial space to
enhance the movement of endolymph into the interstitial space. In
contrast, levels of the homogenous substance increased in response
to inner ear volume depletion, which enhanced the movement of
fluid from the interstitial space to the lumen of the ES. This
response occurs within a matter of minutes and has been observed
after systemic treatment with glycerol in several animal experi-
ments [15,16]. The homogeneous substance is believed to be
originated from the light cells, a type of ES epithelial cell and is
degraded by macrophages. The homogeneous substance is
believed to contain macromolecular complexes that consist of
proteoglycans [10,11] or glycoproteins [17,18], which have been
detected by autoradiographic methods through the uptake of
radioactive sulfur [10]. However, no comprehensive study has
been performed to identify the components of this substance.
According to our results, we believe that the homogeneous
substance is primarily composed of the albumin-like proteins.
Albumin undergoes glycosylation [19] and contains disulphide
bonds [20], characteristics similar to the homogeneous substance
described above. In EVA patients, head trauma or noise exposure
can induce labyrinthine hemorrhage, which consequently increas-
es the protein concentration and volume of the endolymph [8,21].
Subsequently, a sudden loss of hearing is frequently manifested
[22]. In our series of experiments, most patients who displayed a
definite history of sudden hearing deterioration within the prior 6
months showed a decreased proportion of the albumin-like
proteins in their luminal ES fluid. In contrast, patients without
recent hearing deterioration showed a higher proportion of
albumin-like proteins. We speculate that levels of albumin-like
proteins decreased in response to inner ear fluid volume or protein
increases to regulate inner ear fluid volume by decreasing the
Table 3. Ten most abundant protein spots that were not found in human plasma but were found in the luminal fluid of the
endolymphatic sac from patient 2 by MALDI-TOF MS.
Spot No. gi number Protein Name Volume (%)
1 gi|51476390 Hypothetical protein* 61.639
2 gi|51476390 Hypothetical protein 5.272
gi|11493459 PRO 2619
10 gi|145701028 hypothetical protein LOC55471 isoform 3 0.844
13 gi|221043908 unnamed protein product 0.484
14 gi|19923727 minichromosome maintenance complex component 8 isoform 1 0.204
15 gi|15395290 axonemal beta heavy chain dynein type 11 0.2
16 gi|119597447 KIAA1505 protein, isoform CRA_a 0.197
4 gi|51476390 hypothetical protein 0.197
5 gi|51476390 hypothetical protein 0.162
17 gi|224458284 Rho GTPase activating protein 23 0.12
*, hypothetical protein (gi|51476390) was finally revealed to be a mixture of albumin-like proteins by LC-MS/MS (See table 4, figure 6, and figure S1).
doi:10.1371/journal.pone.0021656.t003
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magnitude of the osmotic gradient. In this study, the maximum
difference of osmotic pressure induced by albumin concentration
change is 0.88mOsm/kg; the osmotic pressure induced by
albumin can be roughly calculated in patient 1, in whom the
volume of luminal fluid was stable, as 0.88 mOsm/kg [(960mg/dl
60.617)/67,000 (molecular weight of albumin)], and as nearly 0
mOsm/kg in patient 7, in whom hearing deterioration had
recently occurred. Although other factors may contribute to the
osmotic gradient between the luminal fluid and interstitial fluid, it
seems that the osmotic pressure change induced by the albumin-
like proteins plays an important role in the exchange of fluid
between the two compartments, as does occur in other parts of the
human body. At first, the most abundant protein spot (spot 1 in
Fig. 5) was identified as hypothetical protein (gi|51476390) by
MALDI-TOF MS, which is similar to human serum albumin. The
protein spot area represented 61.6% of total spots in the 2-DE
imaging. In addition to spot 1, four other spots (spots 2, 3, and
4, Fig. 5) were revealed as the same protein. However, it is
reasonable that one spot on 2-DE image contains more than one
protein, so we performed LC-MS/MS to confirm the protein
component of spot 1, which was finally identified as a mixture of
albumin-like proteins. The LC-MS/MS result is likely to be more
Figure 6. Identification of the most abundant protein spot on the 2-DE by LC-MS/MS (patient 1). Spot 1 on the 2-DE image of Figure 5
and trypsinized protein of patient 1 was analyzed by LC-MS/MS. Proteins were identified from the peptide mass maps using MASCOT to search the
protein data bases of Swiss Prot (version 44.1) and GenBank. The protein commonly detected in both samples (part of spot 1 and trypsinized protein
of patients 1) was revealed to be unnamed product (gi|28590) by MASCOT (http://www.matrixscience.com/search_form_select.html). It is similar to
human albumin (gi|4502027) but has five different amino acids out of 609 total amino acids. Comparison of the amino acid sequences was performed
with MultAlin (http://multalin.toulouse.inra.fr/multalin/multalin.html). The amino acid sequence shown in the first row is the unnamed protein
product (gi|28590), the second row is human serum albumin (gi|4502027) and the third row is the consensus between the two. Identified sequences
are marked with green rectangle and blue ones are the unique sequence of the unnamed protein product (gi|28590). Arrows indicates the peptides
for the unnamed protein product (gi|28590) of which the ion scores more than 42 (P,0.05).
doi:10.1371/journal.pone.0021656.g006
Proteomic Analysis of Endolymphatic Sac Fluid
PLoS ONE | www.plosone.org 7 June 2011 | Volume 6 | Issue 6 | e21656
reliable since Peptide Mass Fingerprinting (PMF)-based protein
identification can run into difficulties with protein mixtures, low
abundant amounts of protein, and post-translational modifica-
tions. Thus, it has been found that MS/MS-based protein
identification is more accurate than PMF-based identification
[23]. We also identified four albumin-like proteins in controls, and
two of them exactly coincided with the unnamed protein product
(gi|28590) and the chain A, crystal structure of human serum
albumin (gi|3212456) in the luminal fluid of EVA patients,
respectively. Consequently, albumin-like proteins are thought to
normally exist in the luminal fluid ES and play an important role
in regulating inner ear fluid volume in pathologic conditions by
creating an osmotic gradient between the luminal and interstitial
spaces.
Protein analysis of the luminal fluid of guinea pig ES has been
previously reported [9]. In that study, protein profiles of the luminal
fluid via 2-DE showed that the major plasma proteins were also
found in the luminal fluid. This result was similar to the results of
our study; however, we found that the protein profile was very
different between the luminal fluid and plasma following MARC. In
addition, the previous study did not perform MS to identify these
proteins. The most abundant protein in the luminal fluid was found
to be albumin-like proteins, but most of them differ from the form of
human plasma albumin. These proteins did not disappear even after
MARC, which is different from the case of plasma. There are
several possibilities as to why this protein was not filtered. First, it is
possible that the amount of albumin-like proteins was too high and
could not be filtered completely. However, it does not seem
probable because the protein and albumin concentration of the ES
luminal fluid is not higher than plasma. Second, the conventional
MARC we used was for human plasma samples and so the ES
luminal fluid might not have been filtered effectively. Third, the
epitope of the albumin-like proteins in the ES luminal fluid might
have been different from that of plasma albumin, resulting in the
ineffective filtering of the albumin-like proteins by MARC. If the
third possibility is correct, it suggests that the ES luminal fluid
albumin-like proteins and plasma albumin are likely to be different.
Besides albumin-like proteins such as the unnamed protein product
(gi|28590), unnamed protein product (gi|194391080) and un-
named protein product (gi|194391112), several other proteins that
were not found in the plasma were found in the luminal fluid. These
proteins included: hypothetical protein LOC5547 isoform 3
(gi|145701028), which is identical to protein midA homolog
mitochondrial isoform 3, a kind of mitochondrial protein (http://
www.ncbi.nlm.nih.gov/protein/145701028); unnamed protein
product (gi|221043908), which is a protein similar to the ligand
binding domain of the retinoid X receptor (http://www.ncbi.nlm.
nih.gov/nuccore/221043907); minichromosome maintenance
complex component 8 isoform 1 (gi|19923727), which is involved
in cell cycle transcription (http://www.ncbi.nlm.nih.gov/sites/
entrez?db = gene&cmd = retrieve&list_uids = 84515); axonemal be-
ta heavy chain dynein type 11 (gi|15395290), which is a
microtubule-tubule dependent motor ATPase that is involved in
the movement of cilia (http://www.ncbi.nlm.nih.gov/sites/
entrez?db = gene&cmd = retrieve&list_uids = 8701); KIAA1505
protein, isoform CRA_a (gi|119597447), a protein coded from
CCDC146 (coiled coil domain containing 146) with an unknown
function (http://www.ncbi.nlm.nih.gov/protein/119597447); and
Rho GTPase activating protein 23 (gi|224458284), which is
involved in signal transduction through transmembrane receptors
(http://www.ncbi.nlm.nih.gov/protein/224458284). The ES has
been shown to contain cellular components originated from inner
ear compartments. Considerable evidence has been reported to
indicate that damaged inner ear tissues and cells (including
degraded otoconia-like or stereocilia-like structures) are found in
the human ES [24]. These tissues and cells are thought to be
removed by macrophages and epithelial cells of the ES through
phagocytic activity [15,25]. Therefore, the proteins listed above are
likely derived from cellular components of the luminal fluid of the
ES or involved in signal transduction by binding to specific
molecules of the inner ear. Our results indicate that the luminal fluid
of the ES not only contains several identical proteins to plasma but
also contains proteins that were not identified in plasma. This
implies that the luminal fluid of the ES is originated from both
plasma and the inner ear. To clarify the origin of luminal fluid,
protein profiles of human perilymph and CSF should be
comprehensively analyzed. However, obtaining sufficient peri-
lymph and CSF for protein analysis from EVA patients may give
rise to ethical problems. Additionally, perilymph samples can be
easily contaminated by surrounding tissue fluids and CSF through
the cochlea aqueduct.
This is the first report that has analyzed and identified the
protein profile of luminal fluid from the human ES. It is tempting
to speculate that the proteins in the ES luminal fluid are originated
from both the plasma and the inner ear. Among the proteins in the
luminal fluid, presumably, the albumin-like proteins contributes to
the regulation of inner ear fluid volume by creating an osmotic
gradient between the luminal fluid of the ES lumen and the
surrounding interstitial space, which may be especially important
during pathological conditions such as endolymphatic hydrops.
Table 4. Unique peptide sequences for the albumin-like
unnamed protein product (gi|28590) identified by LC-MS/MS.




Nominal mass of the unnamed protein product (gi|28590) is 69295, calculated
pI value in Mascot search was 5.92, and sequence coverage was 66%. MS/MS
spectra of above peptides are provided in figure S1.
doi:10.1371/journal.pone.0021656.t004
Figure 7. The relationship of albumin-like proteins and total
protein concentration in the luminal fluid of the endolym-
phatic sac. The proportion of total protein tended to be more
represented by albumin-like proteins as the protein concentration of
the luminal fluid increased. (Y = 0.05X + 4.48, P = 0.048, R2 = 0.30).
doi:10.1371/journal.pone.0021656.g007
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Figure 8. 2-DE image of patients with recent (,6 months) hearing deterioration. The proportion of albumin-like proteins in patients with
recent hearing deterioration decreased. Red circles in the figure represent albumin-like proteins. A: 2DE image of patient 3; B: 2DE image of patient 7;
C: 2DE image of patient 8; D: 2DE image of patient 10.
doi:10.1371/journal.pone.0021656.g008
Figure 9. Differences in the proportions of albumin-like proteins. A: The proportion of albumin-like proteins in patients without recent (,6
months) hearing deterioration was 39.766.4%, whereas the proportion of albumin-like proteins in patients with recent hearing deterioration was
14.5611.7%. The proportion of albumin-like proteins was decreased in patients with recent hearing deterioration (P = 0.034). B: The proportion of
albumin-like proteins in patients with the SLC26A4 mutation was 35.6 639.766.4%, whereas the proportion of albumin-like proteins in patients
without the SLC26A mutation was 21.669.0%. The proportion of albumin-like proteins did not differ significantly according to mutation status.
doi:10.1371/journal.pone.0021656.g009
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Materials and Methods
Subjects
This study was approved by the institutional review board of the
Yonsei University College of Medicine and informed written
consent was obtained from each of the participants. Among the
patients with profound hearing loss who visited Severance
Hospital for cochlear implantation from January, 2009 to July,
2010, a total of 11 sequential patients with bilateral EVA (as
confirmed by TBCT and MRI) as a disease group and two
patients with acoustic schwannoma as a control group were
enrolled in the study. The patients with EVA displayed hearing
thresholds greater than 100 dB on pure tone audiogram or
auditory brainstem response. Vestibular function was preserved
according to the caloric test in six patients after surgery. All
patients underwent molecular testing for the SLC26A4 and GJB2
mutations. Seven patients were found to have homogenous or
compound heterogeneous mutations of SLC26A4. One patient
was found to have compound heterogeneous GJB2 mutations and
three patients did not showed any mutations upon molecular
testing (Table 1). Four patients (Patient 3, 7, 8 and 10) had a
definitive history or audiogram of sudden hearing loss within 6
months prior to cochlear implantation. They did not undergo any
medical treatment for sudden hearing loss, and their hearing did
not improve before surgery. Seven patients did not display sudden
hearing loss within 2 years prior to cochlear implantation.
Sampling of blood and ES luminal fluid
During cochlear implantation, the ES was minimally exposed
by the thinning and peeling off of the bony covering (Fig. 11A).
Bleeding from the tissue was carefully controlled with a 0.001%
epinephrine soaked cotton ball and dried to avoid contamination
from blood and tissue fluids. The sac was punctured with a 30-
gauge needle syringe and luminal fluid was gently aspirated
(200,300 ml) (Fig. 11B). The luminal fluid from the ES of the
controls was obtained during acoustic tumor surgery via a
translabyrinthine approach. Because the amount of luminal fluid
in normal ES is too small (,4 ml) [26], direct aspiration without
contamination from normal ES was very difficult. Therefore, we
infused 200 ml of normal saline into the ES and then immediately
aspirated approximately the same volume of injected fluid. All
fluid samples were immediately stored at 280uC until analysis.
Peripheral blood was sampled in an ethylenediaminetetraacetic
acid containing tube for 2-DE analysis from one of the patients
(Table 1, patient 1). Plasma was separated from the blood
immediately and was stored at 280uC until analysis.
Preparation of samples for 2-DE
Whole luminal fluid (150 ml) from the ES or plasma of EVA
patients was desalted by trichloroacetic acid (TCA)/acetone
precipitation. First, 50% (w/v) TCA (Sigma, St. Louis, MO) was
added to reach a final TCA concentration of 5–8%. The sample
was centrifuged at 14,000 g for 15 min and the supernatant was
discarded. Then 200 ml of cold acetone was added. After
incubation for 15 min on ice, the sample was centrifuged at
Figure 10. 1-DE of the luminal fluid from the endolymphatic
sac of controls. The luminal fluid from the endolymphatic sac of
controls was obtained during acoustic tumor surgery via a translabyr-
inthine approach. The highest signal band was excised (red line) and
liquid chromatography mass spectrometry was performed. The
molecular weight of the band corresponded to the albumin-like
proteins from the 2-DE analysis.
doi:10.1371/journal.pone.0021656.g010
Table 5. Albumin or albumin-like protein identified by LC-MS/MS in the luminal fluid from a normal endolymphatic sac.
gi number protein name Mr pI C (%)
gi|3212456 Chain A, Crystal Structure Of Human Serum Albumin 66472 5.67 52
gi|4502027 Serum albumin preproprotein [Homo sapiens] 69366 5.92 50
gi|78101694 Chain A, Human Serum Albumin Complexed With Myristate And Azapropazone 66444 5.57 52
gi|28590 unnamed protein product [Homo sapiens] 69295 5.92 50
Mr, nominal mass; pI, calculated pI value in Mascot search; C, sequence coverage.
doi:10.1371/journal.pone.0021656.t005
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14,000 g for 15 min and the acetone was discarded. The
remaining pellet was dried and dissolved in the sample buffer for
2 DE. We used multiple affinity removal columns (MARC,
Agilent, Palo Alto, CA) to deplete the most abundant proteins (i.e.,
albumin, transferrin, IgG, IgA, haptoglobin, and anti-trypsin) in
the endolymph and blood samples. However, this procedure was
not used for the sample from patient 8, as the protein
concentration was too low (total 152 mg of protein separated). A
4.66100 mm MARC with a binding capacity for 20 ml of human
plasma was used for MARC. Chromatographic separation of the
abundant proteins by MARC was carried out using a mobile
phase reagent kit according to a standard LC protocol provided by
the manufacturer. Crude samples were diluted five times with
Buffer A containing protease inhibitors (COM-PLETETM, Roche,
Branchburg, NJ) and filtered through 0.22 mm spin filters by
spinning at 16,000 g at room temperature for 1–2 min. The
sample was injected and flow-through fractions were collected and
stored at 220uC until use. To resolve depleted proteins on 2-D
gels, flow-through fractions from MARC were pooled and
precipitated with a pre-cooled solution of 10% TCA for 1 h at
220uC. After washing with ice-cold acetone, the pellets were
resolublized in the 2-DE sample buffer. The protein concentration
was quantified by the Bradford protein assay following MARC.
2-DE
2-DE was carried out essentially as described [13]. Aliquots in
sample buffer (7 M urea, 2 M thiourea, 4.5% CHAPS, 10 mM
DTE and 40 mM Tris, pH 8.8) were applied to immobilized pH 3–
10 nonlinear gradient strips (Amersham Biosciences, Uppsala,
Sweden). Isoelectric focusing was performed at 80,000 Vh. The
second dimension was analyzed on 9–16% linear gradient
polyacrylamide gels (18 cm 620 cm 61.5 cm) at a constant 40
mA per gel for approximately 5 hours. After protein fixation in 40%
methanol and 5% phosphoric acid for 1 hr, the gels were stained
with Coomassie Brilliant Blue (CBB) G-250 for 12 hours (except for
patient 7 where the protein concentration was 152 mg and silver
staining was performed). The gels were destained with H2O,
scanned in a Bio-Rad GS710 densitometer and converted into
electronic files.
Identification of protein by matrix-assisted laser
desorption/ionization - time of flight mass spectrometer
(MALDI-TOF MS)
For 2-D gel mapping of the luminal fluid proteome, 58 major
proteins were identified by mass finger printing or by matching
with various internal 2-DE maps. Protein spots excised from 2-
DE gels were destained, reduced, alkylated and digested with
trypsin (Promega, Madison, WI) as previously described [27]. For
MALDI-TOF MS analysis, the peptides were concentrated by a
POROS R2, Oligo R3 column (Applied Biosystems, Fostercity,
CA, USA). After washing the column with 70% acetonitrile,
100% acetonitrile and then 50 mM ammonium bicarbonate,
samples were applied to the R2, R3 column and eluted with
cyano-4-hydroxycinamic acid (CHCA) (Sigma, St. Louis, MO)
dissolved in 70% acetonitrile and 2% formic acid onto the
MALDI plate (Opti-TOFTM 384-well Insert, Applied Biosys-
tems). MALDI-TOF MS was performed on 4800 MALDI-TOF/
TOFTM Analyzer (Applied Biosystems) equipped with a 355-nm
Nd:YAG laser. The pressure in the TOF analyzer is approxi-
mately 7.6e-07 Torr. The mass spectra were obtained in the
reflectron mode with an accelerating voltage of 20 kV and sum
from either 500 laser pulses and calibrated using the 4700
calibration mixture (Applied Biosystems). Proteins were identified
from the peptide mass maps using MASCOT (http://www.
matrixscience.com/search_form_select.html), which searched the
protein databases of the NCBI non-redundant human database
containing 115818 entries(downloaded on 05/09/2009). To
confirm the results of MALDI-TOF MS, especially spot 1 which
occupied the largest part in 2-DE image (Fig. 5), liquid column
mass spectrometry (LC-MS/MS) with the part of spot 1 in 2-DE
of patient 1 was performed as described below. This result was
confirmed by comparing the result of LC-MS/MS with the
trypsinized protein from patient 1(Fig. 5).
1-DE
The volume of luminal fluid obtained from normal ES was too
small to perform 2-DE analysis. Therefore, we performed 1-DE to
examine whether the major proteins in the luminal fluid of the
normal ES were the same as those in the luminal fluid of EVA
patients. Because the protein concentration of the diluted luminal
fluid aspirated during surgery was too small for protein analysis,
two samples from two normal ES were loaded together. The total
amount of protein in the diluted luminal fluid was 25.3 mg for one
sample. We did not use MARC for these samples due to the small
amount of total protein. The samples were lyophilized and
dissolved in 15 ml of distilled water. Samples were subjected to
SDS gel electrophoresis on a 12% polyacrylamide gel and stained
with CBB. The gel band for the most prominent protein was
excised. After reduction with DTT and alkylation with iodoace-
tamide, the band was treated with trypsin to digest the proteins in
situ. Bands were washed with 10 mM ammonium bicarbonate and
50% ACN, swollen in digestion buffer containing 50 mM
ammonium bicarbonate, 5 mM CaCl2, and 1 mg of trypsin,
Figure 11. Sampling of the luminal fluid from the endolymphatic sac of EVA patients. The endolymphatic sac was exposed minimally by
the thinning and peeling off of the bony covering (A) and the sac was punctured with a 30-gauge needle syringe. The luminal fluid was then gently
aspirated (B).
doi:10.1371/journal.pone.0021656.g011
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which were then incubated at 37uC for 12 hours. Peptides were
recovered by two cycles of extraction with 50 mM ammonium
bicarbonate and 100% ACN. The resulting peptide extracts were
pooled, lyophilized and stored at 220uC. To identify the protein
profile of 1-DE bands, LC-MS/MS was performed.
Identification of proteins by liquid column mass
spectrometry (LC-MS/MS)
Nano LC–MS/MS analysis was performed on an agilent 1100
Series nano-LC and LTQ- mass spectrometer (Thermo Electron,
San Jose, CA). The capillary column used for LC–MS/MS analysis
(150 mm 60.075 mm) was obtained from Proxeon (Odense M,
Denmark) and slurry packed in house with 5 mm, 100 A˚ pore size
Magic C18 stationary phase (Michrom Bioresources, Auburn, CA).
The mobile phase A for the LC separation was 0.1% formic acid in
deionized water and the mobile phase B was 0.1% formic acid in
acetonitrile. The chromatography gradient was set up to give a
linear increase from 5% B to 35% B in 100 min and from 40% B to
60% B in 10 min and from 60% B to 80% B in 20 min. The flow
rate was maintained at 300 nL/min after splitting. Mass spectra
were acquired using data-dependent acquisition with full mass scan
(400–1800 m/z) followed by MS/MS scans. Each MS/MS scan
acquired was an average of one microscans on the LTQ. The
temperature of the ion transfer tube was controlled at 200uC and
the spray was 1.5.0–2.0 kV. The normalized collision energy was set
at 35% for MS/MS. Mass tolerances of 1.2 Da and 0.6 Da were
used for precursor and fragment ions, respectively. Peptides were
allowed to be variably oxidized at methionine residues and to be
variably carboxymethylated at cystein.
Data analysis
Detection and determination of volume (%) for each spot was
performed with Image Master Platinum 5 (GE Healthcare,
Piscataway, NJ). Data are presented as the mean values 6 SE.
Significance between two groups was calculated with an unpaired
t-test and the relationship between the total protein concentration
and the proportion of the unnamed protein product (gi|28590)
was analyzed with linear regression. Differences and linear
relationships were considered significant at p,0.05.
Supporting Information
Figure S1 MS/MS spectra of unique peptide sequences
for unnamed protein product (gi|28590) revealed by LC-
MS/MS. A: MS/MS spectrum of amino acid sequence from 311-
337 (peptide sequence: SHCIAEVENDEMPADLPSLAADFVESK,
ion socre:45). B: MS/MS spectrum of amino acid sequence from
438-452 (peptide sequence: KVPEVSTPTLVEVSR, ion score:57).
C: MS/MS spectrum of amino acid sequence from 470-490 (peptide
sequence: RMPCAEDYLSVVLNQLCVLHEK, ion score: 57).
(TIF)
Table S1 Albumin-like proteins identified by LC-MS/
MS except unnamed protein product (gi|28590) in each
sample from part of spot 1 (Fig. 5) and trypsinized
protein of patients 1.
(XLS)
Table S2 Albumin or albumin-like proteins identified
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